MIRM · NASDAQ · STOCK
Mirum Pharmaceuticals, Inc.
$98.27
52W $63.23 – $130.00
56/100
$5.99B
-6.8
0.51
Is MIRM Bullish or Bearish?
Mixed.
Innellis AI committee rates Mirum Pharmaceuticals, Inc. (MIRM) Watch with a composite score of 56/100
, based on 6 analysts with 50% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +3.62 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -16.38 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 44.0% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 13.0x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 44.0% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.15 across 11 articles, 14d) — News
Bear Case
- Price-to-book of 13.0x prices in significant intangible value — Value
- ROE of only -289.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 28.1% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
56/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 73%
of 192 Healthcare peers
Value Analyst
bearish
30
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 13.0x prices in significant intangible value
Growth Analyst
bullish
85
/ 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 44.0% YoY -- genuine top-line momentum
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 28.1% signals elevated volatility
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.15 across 11 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
33.9
Neutral
MACD Histogram
-1.770
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$90.59
Resistance
$109.00
Bollinger %B
0.13
Inside Bands
Price vs Moving Averages
EMA 9
$102.43
Below
EMA 21
$107.44
Below
EMA 50
$108.38
Below
EMA 200
$94.66
Above
Fundamental Analysis
Valuation
100
Profitability
25
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-6.8×
P/B Ratio
—
PEG Ratio
0.00
Dividend Yield
0.00%
52W High
$130.00
52W Low
$63.23
Quality & Growth
ROE
-742.4%
ROA
-277.2%
Gross Margin
8170.1%
Operating Margin
-1741.9%
Revenue Growth YoY
—
Debt / Equity
—
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -6.7 (inexpensive relative to a 15-40x range); Price-to-book of -597.3x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -7.4%; Return on assets of -2.8%; Net margin of -139.2%; Gross margin of 81.7%; Current ratio of 2.86 (healthy short-term liquidity); Debt-to-equity of -72.97; Free cash flow per share is negative (-7.23); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full MIRM Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →